Dr. Eric I. Marks, M.D.
Medical Oncology (Medical Oncology Physician)
830 Harrison Ave, 3rd Fl, Moakley, Hematology/oncology
Boston, MA 02118
- Medicare participating
At a glance
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 53
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MA license 282064 -
Hematology (Internal Medicine) Physician
MA license 282064 -
Internal Medicine Physician
MA license 282064
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 53
- Services billed
- 199
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 75 | 24 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 27 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 20 | 19 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Boston, MA | 33 |
| Prochlorperazine Maleate Other prescribers in Boston, MA | 32 |
| Loperamide (loperamide hcl) Other prescribers in Boston, MA | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $120,365 in research payments for these studies, mostly to the institutions running them.
- A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Deciphera Pharmaceuticals Inc. · Active, not recruiting · NCT05734105 - Phase II single arm study of durvalumab and bevacizumab following transarterial radioembolization using yttrium 90 glass microspheres therasphere in unresectable hepatocellular carcinoma amenable to locoregional therapy
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.